Jump to:

Shield Therapeutics Fundamentals

Company Name Shield Therapeutics Last Updated 16 Jul 2019
Industry Health Care Sector Pharmaceuticals
Shares in Issue (m) 117.19 Market Cap (£m) 124.81
PE Ratio -69.16 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -1.54 EPS Growth (%) 90.94
PEG -0.76 DPS Growth (%) n/a
Debt Ratio 0.00 Debt Equity Ratio 0.00
Net Gearing -15.73 Gross Gearing 6.80
Asset Equity Ratio 1.07 Cash Equity Ratio 24.18
Quick Ratio 4.17 Current Ratio 4.21
Price To Book Value 3.09 ROCE -12.74

Shield Therapeutics Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Shield Therapeutics Company Financials

Assets (£m) 2018 2017 2016
Tangible Assets 0 0 0
Intangible Assets 31 30 29
Investments 0 0 0
Total Fixed Assets 31 30 29
Stocks 0 0 0
Debtors 1 2 2
Cash & Equivalents 10 13 21
Other Assets 2 0 0
Total Assets 43 45 52
Liabilities (£m) 2018 2017 2016
Creditors within 1 year 3 4 4
Creditors after 1 year 0 0 0
Other Liabilities 0 0 0
Total Liabilities 3 4 4
Net assets 40 41 48
Equity (£m) 2018 2017 2016
Called up share capital 2 2 2
Share Premium 88 88 78
Profit / Loss -5 -21 -16
Other Equity 28 28 31
Preference & Minorities 0 0 0
Total Capital Employed 40 41 48
Ratios 2018 2017 2016
Debt Ratio 0.00 0.00 0.00
Debt-to-Equity 0.00 0.00 0.00
Net Gearing -15.73 -21.21 -32.43
Gross Gearing 6.80 8.37 7.61
Assets / Equity 1.07 1.09 1.08
Cash / Equity 24.18 32.27 43.35
EPS -1.54 -17.00 -15.00
Cash Flow (£m) 2018 2017 2016
Cash from operating activities -0 -16 -10
Cashflow before financing -4 -20 -13
Increase in Cash -4 -8 20
Income (£m) 2018 2017 2016
Turnover 12 1 0
Cost of sales 0 0 0
Gross Profit 12 0 0
Operating Profit -5 -21 -12
Pre-Tax profit -5 -21 -16
Profit / Loss for the year 2 2 2

Shield Therapeutics Company Background

Sector Pharmaceuticals
Activities Shield Therapeutics plc is a de-risked commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27 July 2019.
Latest Interim Date 19 Sep 2018
Latest Fiscal Year End Date 03 Apr 2019

Shield Therapeutics Directors

Appointed Director Position
03 Sep 2015 Carl Andrew Sterritt Chief Executive Officer
26 Feb 2016 James Karis Non-Executive Chairman
26 Jul 2018 Hans-Peter Hasler Non-Executive Director
26 Feb 2016 Peter Llewellyn-Davies Non-Executive Director
06 Apr 2018 Rolf Karl Heinz Hoffmann Non-Executive Director

Shield Therapeutics Contact Details

Company Name Shield Therapeutics
Company Address Bentinck House, 3-8 Bolsover Street, London W1W 6AB.
Company Telephone +44 (0)207 186 8500
Company Website http://www.shieldtherapeutics.com/

Shield Therapeutics Advisors

Auditor Name KPMG Audit
Auditor Address 2 Cornwall Street, Birmingham B3 2DL.
Auditor Website http://www.kpmg.com/
Auditor Telephone +44 (0)1212 323 000
Registrar Name Capita Registrars
Registrar Address The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU.
Registrar Website http://www.capitaregistrars.com/
Registrar Telephone 0870 162 3100
Broker Name Liberum Capital
Broker Address City Point, 10th Floor, 1 Ropemaker Street, London EC2Y 9HT.
Broker Website http://www.liberumcapital.com/
Broker Telephone +44 (0)20 3100 2000
Adviser Name Liberum Capital
Adviser Address City Point, 10th Floor, 1 Ropemaker Street, London EC2Y 9HT.
Adviser Website http://www.liberumcapital.com/
Adviser Telephone +44 (0)20 3100 2000
Solicitor Name Stephenson Harwood
Solicitor Address One, St Pauls Churchyard, London EC4M 8SH.
Solicitor Website http://www.stephensonharwood.com/
Solicitor Telephone +44 (0)20 7329 4422
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a